Anixa Biosciences Announces Issuance of Additional U.S. Patent for Ovarian Cancer Vaccine Technology
Anixa Biosciences (NASDAQ: ANIX) announced the upcoming issuance of U.S. Patent Number 12,357,593 on July 15, 2025, strengthening its intellectual property portfolio for ovarian cancer vaccine technology. The patent covers methods of eliciting immune responses targeting anti-Müllerian hormone receptor, type II (AMHR2), a key target for ovarian cancer prevention and treatment.
The vaccine technology, developed in collaboration with Cleveland Clinic and the National Cancer Institute, focuses on preventing and treating ovarian cancer, particularly in high-risk populations with BRCA mutations or family history. The patent, issued to Cleveland Clinic with Anixa holding worldwide rights, includes methods for administering immunogenic compositions comprising nucleic acid encoding AMHR2 polypeptide.
Anixa Biosciences (NASDAQ: ANIX) ha annunciato l'imminente rilascio del brevetto statunitense numero 12.357.593 previsto per il 15 luglio 2025, rafforzando il suo portafoglio di proprietà intellettuale relativo alla tecnologia del vaccino per il cancro ovarico. Il brevetto copre metodi per stimolare risposte immunitarie mirate al recettore dell'ormone anti-Mülleriano di tipo II (AMHR2), un obiettivo chiave per la prevenzione e il trattamento del cancro ovarico.
La tecnologia del vaccino, sviluppata in collaborazione con la Cleveland Clinic e il National Cancer Institute, si concentra sulla prevenzione e il trattamento del cancro ovarico, in particolare nelle popolazioni ad alto rischio con mutazioni BRCA o storia familiare. Il brevetto, rilasciato alla Cleveland Clinic con Anixa detentrice dei diritti mondiali, include metodi per la somministrazione di composizioni immunogeniche contenenti acidi nucleici che codificano per il polipeptide AMHR2.
Anixa Biosciences (NASDAQ: ANIX) anunció la próxima emisión de la Patente de EE.UU. Número 12,357,593 para el 15 de julio de 2025, fortaleciendo su cartera de propiedad intelectual para la tecnología de vacunas contra el cáncer de ovario. La patente cubre métodos para inducir respuestas inmunitarias dirigidas al receptor de la hormona anti-Mülleriana tipo II (AMHR2), un objetivo clave para la prevención y tratamiento del cáncer de ovario.
La tecnología de la vacuna, desarrollada en colaboración con la Cleveland Clinic y el National Cancer Institute, se centra en prevenir y tratar el cáncer de ovario, especialmente en poblaciones de alto riesgo con mutaciones BRCA o antecedentes familiares. La patente, emitida a la Cleveland Clinic con Anixa poseyendo derechos mundiales, incluye métodos para administrar composiciones inmunogénicas que comprenden ácidos nucleicos que codifican el polipéptido AMHR2.
Anixa Biosciences (NASDAQ: ANIX)는 2025년 7월 15일 미국 특허 번호 12,357,593의 발행 예정을 발표하며 난소암 백신 기술에 대한 지적 재산권 포트폴리오를 강화했습니다. 해당 특허는 난소암 예방 및 치료의 핵심 표적인 항-뮐러관 호르몬 수용체 II형(AMHR2)을 표적으로 하는 면역 반응 유도 방법을 포함합니다.
이 백신 기술은 Cleveland Clinic 및 National Cancer Institute와 협력하여 개발되었으며, BRCA 돌연변이 또는 가족력이 있는 고위험군에서 난소암 예방 및 치료에 중점을 둡니다. 이 특허는 Cleveland Clinic에 발행되었으며 Anixa가 전 세계 권리를 보유하고 있으며, AMHR2 폴리펩타이드를 암호화하는 핵산을 포함하는 면역원성 조성물 투여 방법을 포함합니다.
Anixa Biosciences (NASDAQ: ANIX) a annoncé la prochaine délivrance du brevet américain numéro 12 357 593 prévue pour le 15 juillet 2025, renforçant ainsi son portefeuille de propriété intellectuelle pour la technologie du vaccin contre le cancer de l'ovaire. Le brevet couvre des méthodes visant à provoquer des réponses immunitaires ciblant le récepteur de l'hormone anti-Müllérienne de type II (AMHR2), une cible clé pour la prévention et le traitement du cancer de l'ovaire.
La technologie vaccinale, développée en collaboration avec la Cleveland Clinic et le National Cancer Institute, se concentre sur la prévention et le traitement du cancer de l'ovaire, notamment chez les populations à haut risque porteuses de mutations BRCA ou ayant des antécédents familiaux. Le brevet, délivré à la Cleveland Clinic avec Anixa détenant les droits mondiaux, inclut des méthodes d'administration de compositions immunogènes comprenant des acides nucléiques codant pour le polypeptide AMHR2.
Anixa Biosciences (NASDAQ: ANIX) gab die bevorstehende Erteilung des US-Patents Nummer 12.357.593 am 15. Juli 2025 bekannt, wodurch das geistige Eigentumsportfolio für die Technologie eines Eierstockkrebs-Impfstoffs gestärkt wird. Das Patent umfasst Methoden zur Auslösung von Immunantworten, die auf den Anti-Müller-Hormonrezeptor Typ II (AMHR2) abzielen, ein zentrales Ziel für die Prävention und Behandlung von Eierstockkrebs.
Die Impftechnologie, entwickelt in Zusammenarbeit mit der Cleveland Clinic und dem National Cancer Institute, konzentriert sich auf die Prävention und Behandlung von Eierstockkrebs, insbesondere bei Hochrisikopatienten mit BRCA-Mutationen oder familiärer Vorbelastung. Das Patent, das der Cleveland Clinic erteilt wurde und bei dem Anixa die weltweiten Rechte hält, umfasst Methoden zur Verabreichung immunogener Zusammensetzungen, die Nukleinsäuren codierend für das AMHR2-Polypeptid enthalten.
- New patent strengthens intellectual property protection for ovarian cancer vaccine technology
- Worldwide rights secured for the patent through Cleveland Clinic collaboration
- Technology targets high-risk populations with BRCA mutations
- None.
Anixa's ovarian cancer vaccine, being developed in a collaboration between Cleveland Clinic and the National Cancer Institute, represents a novel approach to preventing and treating ovarian cancer, particularly among high-risk populations such as those carrying BRCA mutations or with a family history of the disease.
The patent includes methods of administering an immunogenic composition comprising a nucleic acid encoding the AMHR2 polypeptide, specifically the extracellular domain of human AMHR2, to elicit an AMHR2-specific immune response. This patent was issued to Cleveland Clinic and Anixa exclusively holds the world-wide rights to the patent.
Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences, commented, "The issuance of this patent by the USPTO continues to strengthen broad protection for the various components and delivery mechanisms of our vaccine technology. This patent supports the continued advancement of our program."
About Anixa Biosciences, Inc.
Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor-T cell (CER-T) technology. This technology is differentiated from other cell therapies as the natural ligand of the FSHR receptor, FSH, binds to the FSHR receptor on the tumor cell instead of an antibody fragment. Moffitt is a world leader in cancer immunotherapy treatments, pioneering next-generation cell therapies such as CAR-T, and tumor infiltrating lymphocytes (TILs) to harness the power of the immune system. The Company's vaccine portfolio includes vaccines being developed in collaboration with Cleveland Clinic to treat and prevent breast cancer and ovarian cancer, as well as additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate. These vaccine technologies focus on immunizing against "retired" proteins that have been found to be expressed in certain forms of cancer. The breast and ovarian cancer vaccines were developed at Cleveland Clinic and exclusively licensed to Anixa. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company related to these vaccine technologies. Anixa's unique business model of partnering with world-renowned research institutions on all stages of development allows the Company to continually examine emerging technologies in complementary fields for further development and commercialization. To learn more, visit www.anixa.com or follow Anixa on LinkedIn, X, Facebook and YouTube.
Forward-Looking Statements
Statements that are not historical fact may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical facts, but rather reflect Anixa's current expectations concerning future events and results. We generally use the words "believes," "expects," "intends," "plans," "anticipates," "likely," "will" and similar expressions to identify forward-looking statements. Such forward-looking statements, including those concerning our expectations, involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in "Item 1A - Risk Factors" and other sections of our most recent Annual Report on Form 10-K as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented in this press release.
Contact:
Mike Catelani
President, COO & CFO
mcatelani@anixa.com
408-708-9808
View original content to download multimedia:https://www.prnewswire.com/news-releases/anixa-biosciences-announces-issuance-of-additional-us-patent-for-ovarian-cancer-vaccine-technology-302500651.html
SOURCE Anixa Biosciences, Inc.
FAQ
What patent did Anixa Biosciences (ANIX) receive for its ovarian cancer vaccine?
Who are the development partners for Anixa's ovarian cancer vaccine?
What population does Anixa's ovarian cancer vaccine target?
What are the key components covered in Anixa's new patent?
Who owns the rights to Anixa's new ovarian cancer vaccine patent?
